In November 2013, JAMA published a Veterans Affairs (VA) cohort of 8,709 men with low testosterone who had undergone coronary angiography. Vigen and colleagues reported that the men on testosterone had higher rates of death, myocardial infarction, and stroke.
I practiced through what followed. Men with documented hypogonadism, real symptoms, and the labs to prove it asked me whether their prescription was going to kill them. Some stopped on their own. Some never came back to ask.
The study was already coming apart. It required published corrections to both the cohort and the analysis. Critics found problems with patient exclusions, women counted in a study of men, and a striking gap between crude event rates, which looked better in the treated men, and the adjusted results, which looked worse. Adjustment is legitimate statistics, but every adjustment rests on assumptions, and these got far less scrutiny than they deserved. Abraham Morgentaler and colleagues asked JAMA to retract it, and twenty-five international medical societies joined the request. JAMA declined.
None of that slowed anything down. The Food and Drug Administration (FDA) opened an investigation in January 2014. In March 2015, it required new labeling warning of a possible increased risk of heart attack and stroke, and stated that benefit had not been established for age-related decline. That was a precautionary decision made on contested evidence. Someone would pay for that.
Real physician voices, twice a week
Free, and one click to unsubscribe.
Here is the bill. A 2018 study in JAMA tracked national prescribing. New testosterone users fell 22 percent in the two months after Vigen was published, then dropped by roughly half again after the FDA safety bulletin. Between 2013 and 2016, the number of men on testosterone fell by nearly half. More than 25,000 lawsuits were filed against manufacturers. Treating confirmed hypogonadism became something physicians had to defend rather than simply do.
Then there is the part nobody measured.
In 2015, a study in the European Heart Journal analyzed 83,010 VA men with low testosterone and no prior heart attack or stroke. Men whose levels normalized on treatment had lower all-cause mortality, fewer myocardial infarctions, and fewer strokes than untreated men. Same VA system, same kind of observational data, and the signal ran the other way.
That study was observational too, and I will not claim it proves more than Vigen did. But follow the logic regulators applied in 2014. If one observational association was enough to put a cardiovascular warning on every testosterone label in the country, the same logic demands an answer to a question no one asked: What happened to the men who stopped? Nobody counted. Certainty level: unknown. That silence should bother us more than it does.
The question that mattered required a randomized trial, and it took nearly a decade to get one. TRAVERSE enrolled 5,246 men aged 45 to 80 with symptomatic hypogonadism, repeatedly low testosterone, and established cardiovascular disease or high cardiovascular risk. They were randomized to transdermal testosterone gel or placebo, titrated to a physiologic range. Major adverse cardiovascular events occurred in 7.0 percent of the testosterone group and 7.3 percent of the placebo group. Noninferior.
In February 2025, the FDA removed the cardiovascular risk language from testosterone labeling class-wide and added a warning about increased blood pressure. Prescribing is climbing again. In June 2026, the Department of Health and Human Services went further, requesting removal of the label’s limitation on age-related decline.
What this doesn’t mean: TRAVERSE is not a clean bill of health. Atrial fibrillation, acute kidney injury, and pulmonary embolism were more frequent in the testosterone arm. Erythrocytosis remains dose-dependent and real. And the trial studied gel at physiologic levels in men with confirmed deficiency. It says nothing about supraphysiologic dosing, about men with normal levels chasing performance, or about the injectable protocols sold by commercial low-T clinics. The pendulum is swinging back, and those clinics intend to ride it.
So practice the medicine the evidence actually supports. Confirm deficiency with repeated, properly timed morning levels. Look for reversible causes and contraindications. Treat to physiologic concentrations, not beyond. Monitor hematocrit, blood pressure, and prostate parameters. Ask about palpitations. And tell patients plainly what we know and what we still don’t.
In 2013, a contested association outran its evidence, and men with a treatable deficiency absorbed the consequences for ten years. Alarming research deserves a hearing, but our conclusions should never outrun our evidence, in either direction.
Amir Friedman is a pain physician, physician-scientist, and investigator with 25 years of clinical experience and more than 10,000 patients treated. He trained in surgery, anesthesiology, critical care, and pain medicine at the University of Southern California and the University of California, Los Angeles.
His work focuses on chronic pain, neuromodulation, regenerative medicine, longevity, men’s health, and emerging approaches to chronic disease. He writes about neuroscience, AI-enabled medicine, and the challenge of translating innovation into meaningful patient care.
Friedman also applies his experience in complex chronic illness and care delivery through his work with Broadway Community Care Centers in California, advancing integrated behavioral health care models designed to improve access, coordination, and outcomes for underserved communities. He can be found on LinkedIn.

